Material and methods IVD was performed for 40 treatments planned using intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted into an additional needle. Post-treatment TRUS images were acquired for 20 patients to assess needle movement. Monte Carlo simulations of treatment plans were performed for 10 patients to assess impact of heterogeneities.
Introduction
Evidence of the dose-response relationship in prostate cancer [1] has led to increases in the dose per fraction delivered in high dose rate (HDR) prostate brachytherapy with up to 19 Gy prescribed to the 100% isodose in some monotherapy treatments [2] . It is therefore important to have confidence in the dose that is being delivered and there is increasing interest in performing in-vivo dosimetry (IVD) [3, 4] . UK guidelines recommend that IVD is performed for most radiotherapy patients at the beginning of their treatment [5] . HDR prostate brachytherapy treatments use a single source sequentially stepping through a set of needles and so it could be possible to monitor the treatment in real-time and interrupt and correct if a significant error is detected. In this study the feasibility of this approach is investigated using clinical IVD data from 40 HDR prostate brachytherapy patients.
IVD in HDR prostate brachytherapy has been implemented by Suchowerska et al [6] using a scintillation detector in the urethral catheter and by Seymour et al [7] using a diode array inside a dummy ultrasound probe in the rectum, however these studies did not analyse measured data in terms of real-time per-needle measurements. TLDs have given good results for HDR prostate brachytherapy IVD [8] [9] [10] but do not allow a real time measurement approach. Haughey et al [11] used a metal-oxide semiconductor field effect transistor (MOSFET) linear array inside the rectum during HDR prostate brachytherapy but concluded that the approach was not suitable due to the difficulties of quantifying uncertainties in MOSFET response. IVD in permanent seed implant prostate brachytherapy has also been investigated [12] [13] [14] .
Dose gradients and position uncertainties of sources and detectors result in large and variable uncertainties in brachytherapy IVD. Real-time IVD error detection cannot use a simple error threshold but requires uncertainties to be estimated for individual catheters based on treatment plan data. This was demonstrated by Kertscher et al [15] who used Monte Carlo (MC) simulations of random source position shifts to estimate uncertainties that were applied to measurements with simulated treatment errors.
In this study we report our clinical experience of IVD using a microMOSFET (model TN-502RDM-H Best Medical, Ottawa, Canada, hereafter referred to as MOSFET) inserted into an additional needle during intra-operative trans-rectal ultrasound (TRUS) based HDR prostate
brachytherapy. An uncertainty analysis is performed including MC simulations to assess the impact of heterogeneities on dose, post-treatment imaging to assess the impact of needle movement between planning and treatment delivery, evaluation of position dependent uncertainties and other MOSFET and dose calculation related uncertainties. The uncertainty analysis is used to define error detection thresholds for per-needle and total plan measurements, and these thresholds are retrospectively applied to the IVD results to assess the feasibility of real-time treatment monitoring.
Method

MOSFET calibration and commissioning
MOSFET calibration and commissioning used a 30 cm x 30 cm x 30 cm water tank with additional solid water underneath to ensure adequate scatter.
The tank was fitted with two aligned template grids through which steel needles were inserted to create an accurate, rigid geometry. All measurements were performed using the same Flexitron afterloader (Elekta AB, Stockholm, Sweden) and 192 Ir source used in clinical treatments. For calibration, the MOSFET was placed in a central steel needle and was irradiated using 4 needles arranged at cardinal angles around the MOSFET needle, to minimize dose gradient at the MOSFET position, and with a source-MOSFET distance of 1.5 cm to minimize the energy dependence correction that would need to be applied to clinical measurements. The MOSFET sensitivity factor was determined from the ratio of the MOSFET reading to the expected dose calculated using MC simulation of the water tank setup, using the MC simulation framework described below. Three Gy in 15 fractions of external beam to the prostate and seminal vesicles [16] and 7 patients received a single fraction monotherapy treatment [2] . Plans were prescribed to the prostate D 90 , with 15 Gy and 19 Gy to the 100% isodose levels for boost and monotherapy treatments respectively. Needles were inserted under TRUS guidance, treatments were planned from TRUS images using the Oncentra Prostate™ treatment planning system (TPS) v4.1.3 (Elekta AB), DVH-based inverse optimisation (referred to as DVHO in Oncentra Prostate™) [17] and delivered in a single theatre session with framework that has previously been described [18] using the Flexitron source modeled and benchmarked using data from AAPM report 229 [19] and using MCNPX v2.5.0 [20] . Table III . Dose at the MOSFET position was calculated using a 1 mm diameter spherical water cell (MCNPX F6 tally) and 200-400 million histories (depending on the implant size) were simulated to achieve statistical uncertainty in the tally cell of ~0.5%.
Analysis of post-treatment imaging
To assess the impact of needle movement between planning TRUS image acquisition and treatment (typically ~1 hour), for 20 of the patients, a TRUS volume was acquired immediately after completion of treatment. The needles were reconstructed in the post-treatment images, the dose at the MOSFET position was recalculated using the adjusted needle positions and compared to the original planned dose.
Uncertainty analysis
An uncertainty analysis was performed to estimate per-needle and total plan error detection thresholds. uncertainties were taken from published data [22] . MOSFET reproducibility uncertainty was calculated from the predicted reading for each needle/plan using data on the standard error of sets of repeated measurements at different dose levels, described in supplementary data. Considering mean values for the 40 patients, the total plan measured MOSFET reading was 6.4% lower than predicted (range +5.8% to -14.6%). Figure 1 shows all patient measurements in terms of absolute measured dose. Figure 2a shows one example measurement curve. Mean per-needle reading for the 40 patients was also 6.4% lower than prediction with standard deviation 17.3% and range -129% to +185%. The mean total plan energy dependence correction applied was 1.6% (range 0.5% -3.2%). The mean per-needle energy dependence correction applied was 1.3% (range -
2.3% -4.9%).
Monte Carlo simulations MC simulations showed that the dose at the MOSFET position was on average -1.6% compared to the dose predicted by the TPS (mean for 10 patients, range -1.0% to -2.0%).
Analysis of post-treatment imaging
Post-treatment TRUS images showed either minimal difference in needle positions or some posterior movement of the more posterior needles. In all cases needle displacements were <2 mm. In the post treatment reconstructions on average the dose at the MOSFET position was -1.8% compared to the original treatment plan (mean for 20 patients, range +0.9%
to -5.3%). investigations, the mean difference between measured and predicted total plan reading is -3.0% and the largest difference is -11.2%. Comparable measurements were made by Suchowerska et al [6] using a scintillation detector in the urethral catheter for CT planned treatments and achieved maximum deviation from planned dose of -9% for 10 patients (mean deviation was not stated but from the data presented can be calculated to be -3.3%) and also by Seymour et al [7] using a diode array in the rectum for 28 patients finding 95% of measurements agreeing with predicted dose within ±20%. In this study the MOSFET was placed in an additional needle which gives a stable position that can be accurately reconstructed. However a limitation is that for very small prostates it can be difficult to find a suitable empty template position that does not risk the MOSFET needle perforating the urethra and on approximately five occasions over the period of this study we did not perform IVD for this reason.
Evaluation of error detection thresholds
MC simulations showed that steel needles reduced dose at the MOSFET position by 1.6% which is comparable to a study by Gaudreault et al [24] which found dose reduction of 1.3%. Needle movement in TRUS planning was investigated by Milickovic et al [23] who found an average reduction in urethra D0.1cm 3 of 2.1% compared to a point dose reduction at the MOSFET position (generally close to the urethra) of 1.8% in this study.
MOSFET measurements were ~3% low after these corrections had been applied. This apparently systematic difference could be due to an as yet undetected error in the MOSFET commissioning/calibration process or limitations in ultrasound reconstruction accuracy -the probe remains in the rectum during treatment but there could be differences in implant position compared to image acquisition where the probe is being moved through the rectum and compressing the prostate.
This study has investigated the feasibility of real-time IVD to detect errors during treatment. This requires estimation of measurement uncertainties on a per-needle basis. Per-needle position uncertainty dominates and it is important to avoid falsely detecting an error for needles that are close to the MOSFET so tend to contribute a large proportion of the total dose, and only require a small positional shift to generate a large change in the MOSFET reading. It can be hard to position the MOSFET needle in a low dose gradient region, particularly for small prostates, and the MOSFET reading can be dominated by the contribution of a single needle with large associated uncertainties (in the worst case in this study ~1/3 of the total plan dose to the MOSFET was contributed from a single needle).
Position uncertainty was estimated using an inverse square approximation for a position tolerance of 1mm. This method is simple to implement in a spreadsheet and could easily be calculated between plan approval and treatment delivery. Kertscher et al [15] used random position error simulations to estimate position uncertainties in a statistical manner and found k=1 position uncertainties up to 15.9% compared to 55.1% in this study, however the closest source-detector position was 6 mm compared to 2.7 mm in this study. Although large position uncertainties were derived for some needles in this study these were calculated using position shifts of 1mm which would not be clinically significant [23] . For 91% of the needles analysed, the position uncertainty was < 20%.
In this study ~5% of needle measurements exceeded the error threshold which is appropriate for a k=2 uncertainty level. The majority of these needles had low absolute mV predicted readings, therefore the uncertainty calculation could be under-estimating uncertainty for low readings. To 
MOSFET energy dependence
The MOSFET energy dependent response correction was determined from water tank measurements as described above, but varying the source-MOSFET distance in the range 1 -5 cm. For distances 1 -3 cm the MOSFET was irradiated using 4 needles arranged at cardinal angles around the MOSFET needle, to minimize dose gradient at the MOSFET position, for greater distances this was not possible due to the size of the template so a single source needle was used.
The ratio of MOSFET measurement to the measurement predicted from the MOSFET sensitivity factor using the dose calculated by the TPS was used to determine the MOSFET response relative to the calibration distance of 1.5 cm. A linear fit of response versus distance was used to determine the energy dependence correction. Suppl Figure 2 shows the results. Based on this a 2.6% cm -1 correction was applied to MOSFET predicted readings to correct for the energy dependence. 
